Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;27(4):e377-e385.
doi: 10.3747/co.27.6115. Epub 2020 Aug 1.

Breast cancer diagnosis and treatment wait times in specialized diagnostic units compared with usual care: a population-based study

C Webber  1 , M Whitehead  2 , A Eisen  3 , C M B Holloway  3   4 , P A Groome  2   5
Affiliations

Breast cancer diagnosis and treatment wait times in specialized diagnostic units compared with usual care: a population-based study

C Webber et al. Curr Oncol. 2020 Aug.

Abstract

Background: Breast assessment sites (bass) were developed to provide expedited and coordinated care for patients being evaluated for breast cancer (bca) in Ontario. We compared the diagnostic and treatment intervals for patients diagnosed at a bas and for those diagnosed through a usual care (uc) route.

Methods: This population-based, cross-sectional study of patients diagnosed with bca in Ontario during 2007-2015 used linked administrative data. "Diagnostic interval" was the time from the earliest cancer-related health care encounter before diagnosis to diagnosis; "treatment interval" was the time from diagnosis to treatment. Diagnosis at a bas was determined from the patient's biopsy and mammography institutions. Interval lengths for the bas and uc groups were compared using multivariable quantile regression, stratified by detection method.

Results: The diagnostic interval was shorter for patients who were bas-diagnosed than for those who were uc-diagnosed, with adjusted median differences of -4.0 days [95% confidence interval (ci): -3.2 days to -4.9 days] for symptomatic patients and -5.4 days (95% ci: -4.7 days to -6.1 days) for screen-detected patients. That association was modified by stage at diagnosis, with larger differences in patients with early-stage cancers. In contrast, the treatment interval was longer in patients who were bas-diagnosed than in those who were uc-diagnosed, with adjusted median differences of 4.2 days (95% ci: 3.8 days to 4.7 days) for symptomatic patients and 4.2 days (95% ci: 3.7 days to 4.8 days) for screen-detected patients.

Conclusions: Diagnosis of bca through a bas was associated with a shorter diagnostic interval, but a longer treatment interval. Although efficiencies in the diagnostic interval might help to reduce distress experienced by patients, the longer treatment intervals for patients who are bas-diagnosed remain a cause for concern.

Keywords: Breast neoplasms; diagnostic interval; early detection; organized breast assessment; treatment interval.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.

Figures

FIGURE 1
FIGURE 1
Flow diagram of study cohort creation. OHIP = Ontario Health Insurance Plan.
See this image and copyright information in PMC

References

    1. Weller D, Vedsted P, Anandan C, et al. An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation. BMJ Open. 2016;6:e009641. doi: 10.1136/bmjopen-2015-009641. - DOI - PMC - PubMed
    1. Weller D, Vedsted P, Rubin G, et al. The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. Br J Cancer. 2012;106:1262–7. doi: 10.1038/bjc.2012.68. - DOI - PMC - PubMed
    1. Butler J, Foot C, Bomb M, et al. The International Cancer Benchmarking Partnership: an international collaboration to inform cancer policy in Australia, Canada, Denmark, Norway, Sweden and the United Kingdom. Health Policy. 2013;112:148–55. doi: 10.1016/j.healthpol.2013.03.021. - DOI - PubMed
    1. Rose PW, Rubin G, Perera-Salazar R, et al. Explaining variation in cancer survival between 11 jurisdictions in the International Cancer Benchmarking Partnership: a primary care vignette survey. BMJ Open. 2015;5:e007212. doi: 10.1136/bmjopen-2014-007212. - DOI - PMC - PubMed
    1. Richards MA. The size of the prize for earlier diagnosis of cancer in England. Br J Cancer. 2009;101(suppl 2):S125–9. doi: 10.1038/sj.bjc.6605402. - DOI - PMC - PubMed

Publication types